Pfizer’s Obesity Pipeline Poised to Challenge Novo Nordisk
Pfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
Understanding when index funds are worth it depends on time horizon and fees. This quick guide outlines key scenarios and considerations.
14,180 articlesPfizer is quietly building a GLP-1 obesity pipeline that could alter the competitive landscape, while investors seek ...
A leading investor foresees a future where agentic AI unlocks massive productivity gains, enabling a company to reach...
Oklo is combining AI with nuclear reactor design to shorten development timelines and improve safety. This article br...
Bitcoin hovers around $60,000 as weekend trading begins, with a pivotal options expiry and inflation data in focus. A...
When public figures open up about health issues, it’s more than a story—it’s a blueprint for real-world money moves. ...
A playful plea becomes a genuine acting gig, illustrating how smart side gigs can diversify income. Here’s what perso...
A 62-year-old worker plans to retire after a raise, but discovers a little-known Social Security rule that could limi...
Tesla accelerates margin gains in Q1 2026 as Rivian pushes its R2 strategy through partnerships and new products, hig...
A veteran market strategist argues Big Tech is underappreciated as earnings grow and capital spending remains durable...
Autonomous AI agents paying for goods and services could redefine digital commerce. This article examines how Ripple ...
A 22-year-old seeks guidance on whether a rich friend should pay off his $70,000 debt. Ramsey warns that such help ca...
As July rolls in, space stocks attract attention—but not all rockets rise equally. This guide spotlights two practica...